Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata
02:41pm, Tuesday, 14'th Jun 2022 Zacks Investment Research
Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.
FDA panel to review Moderna vaccine in children aged 6 to 17, and Rolling Stones front man Mick Jagger tests positive for COVID
02:02pm, Tuesday, 14'th Jun 2022 MarketWatch
An independent panel of advisers to the Food and Drug Administration will meet later Tuesday to discuss the use of the Moderna vaccine in children aged 6 to 17.
FDA says Pfizer three-shot vaccine is safe for children under 5, ahead of panel meeting that will also review Moderna's two-shot regimen
12:13pm, Tuesday, 14'th Jun 2022 MarketWatch
Federal health officials said Sunday that Pfizer's COVID-19 vaccine appears safe and effective for children below the age of five, clearing another hurdle on the path toward adding that group to the n
Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy
09:33am, Tuesday, 14'th Jun 2022 Benzinga
Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration.
Eli Lilly & Company (NYSE: LLY) and Incyte Cor
COVID-variant booster from Sanofi, GSK shows promising results
09:13pm, Monday, 13'th Jun 2022 MarketWatch
A COVID-19 vaccine developed by Sanofi SA and GSK PLC to target the Beta strain of the virus produced a stronger antibody response against variants of omicron when given as a booster compared with
Sanofi (SNY), GSK COVID Booster Jab Effective Against Omicron
05:29pm, Monday, 13'th Jun 2022 Zacks Investment Research
Data from clinical studies show that Sanofi (SNY) and Glaxo's (GSK) next-generation COVID-19 booster candidate elicits a stronger immune response in adults who received an mRNA vaccine as a primary re
GSK's RSV Vaccine Candidate Offers Robust Protection in Elderly
01:41pm, Monday, 13'th Jun 2022 Zacks Investment Research
GSK's RSV vaccine candidate for adults aged 60 years or above achieves statistically significant and clinically meaningful efficacy in a phase III study. Regulatory submissions are likely in the secon
Pfizer, BioNTech's COVID Jab Safe in Young Kids Per FDA
01:28pm, Monday, 13'th Jun 2022 Zacks Investment Research
Per the FDA reviewers, the available data supports Pfizer (PFE) and BioNTech (BNTX) vaccine's effectiveness in preventing COVID infection in kids six months to under five years of age as a three-dose
Is This Downtrodden Stock a Value Trap?
12:00pm, Monday, 13'th Jun 2022 The Motley Fool
Probably yes, but it could still be a good purchase for investors with the right mindset.
Moderna Stock: Bull vs. Bear
11:00am, Sunday, 12'th Jun 2022 The Motley Fool
The company has generated billions of dollars in profit and revenue.
Energy stocks are this year's best performers — but they're not on the list of top investment newsletters
11:44am, Saturday, 11'th Jun 2022 MarketWatch
A new sector may soon replace energy at the top of the heap.
Moderna's (MRNA) Omicron-Specific Booster Jab Meets Study Goal
06:32pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Moderna's (MRNA) bivalent COVID booster candidate targeting the Omicron variant achieved all pre-specified endpoints in a phase II/III study.
Here's Why Moderna May Dominate the Vaccine Market This Fall
02:00pm, Thursday, 09'th Jun 2022 The Motley Fool
Moderna is following through on its promises.
Moderna's next-generation COVID-19 booster provides 'superior' protection against omicron
11:25am, Thursday, 09'th Jun 2022 MarketWatch
The company is aiming to make its 'bivalent' COVID-19 booster available to Americans this summer.
Pfizer And 3 Other Stocks Insiders Are Selling
11:06am, Thursday, 09'th Jun 2022 Benzinga
US stock futures traded mixed this morning on Thursday. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it indicates their concern in the company’s prospects
